9713 Key West Ave., Suite 400
About MaxCyte, Inc.
We provide our patented, high-performance cell-engineering platform to biopharmaceutical partners engaged in drug discovery and development, biomanufacturing and cell therapy, including gene editing and immuno-oncology. With our robust delivery platform, our team of scientific experts helps our partners unlock the potential of their products and solve development and commercialization challenges.
This platform allows for the engineering of nearly all cell types, including human primary cells, with any molecule, at any scale. It also provides unparalleled consistency and minimal cell disturbance – facilitating rapid, large-scale, clinical- and commercial-grade cell-engineering in a non-viral system and with low-toxicity concerns. Our cell-engineering platform is FDA-cleared, providing our customers and partners with an established regulatory path to commercialize cell-based medicines.
We are also developing novel CARMA cellular therapies for our own pipeline with our first drug candidate in a Phase I clinical trial. CARMA is MaxCyte’s novel proprietary technology for development of human mRNA-based cellular therapies to treat a broad range of diseases.
Stock Exchange: Alternative Investment Market
Stock Symbol: MXCT
At MaxCyte, we take a collaborative partnering approach with our clients with the goal of rapidly driving our partners’ development efforts forward through to commercial use, more cost-effectively and with lowered risk. We have developed and commercialized MaxCyte Scalable Transfection Systems for high-performance delivery of biomolecules using Flow Electroporation ® Technology, a proprietary cell-engineering technology designed to meet the stringent demands of clinical use – namely, the ability to safely and reproducibly modify primary human cells with high efficiency, low cytotoxicity, and at the scale required to treat patients.
193 articles about MaxCyte, Inc.
MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT) today announced financial results for the first quarter ended March 31, 2023, and updated 2023 revenue guidance.
MaxCyte Signs Strategic Platform License with Walking Fish Therapeutics to Support the Development of its Innovative B Cell Platform
MaxCyte, Inc. today announced the signing of a strategic platform license (SPL) with Walking Fish Therapeutics , Inc. a biotechnology company that is rapidly advancing B cell-based therapeutics.
MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT) today announced that it will release financial results for the first quarter 2023 after the U.S. market close on Wednesday, May 10th, 2023.
MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT) today announced Douglas J. Swirsky has been appointed as the Company’s Chief Financial Officer, effective immediately.
MaxCyte, Inc. announced its fourth quarter and full year ended December 31, 2022, financial results and provided initial 2023 revenue guidance.
MaxCyte Establishcientific Advisory Board Comprised of Globally Recognized Experts in Cell Engineering Enabling Technology
MaxCyte, Inc. today announced the formation of its new Scientific Advisory Board (SAB) that will reflect the cutting edge of research in molecular design and cell engineering.
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Revenue Results and Provides 2023 Revenue Guidance
MaxCyte, Inc. today announced preliminary revenue results for the fourth quarter and full year 2022 and provided initial 2023 revenue guidance.
MaxCyte to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023 and Participate in Upcoming Investor Conferences
MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT) today announced that it will release financial results for the fourth quarter and full year 2022 after the U.S. market close on Wednesday, March 15th, 2023.
MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell Therapy Programs
MaxCyte, Inc. announced the signing of a strategic platform license with Catamaran Bio, Inc., a biotechnology company developing novel, off the-shelf chimeric antigen receptor -NK cell therapies to treat a broad range of cancers, with a primary focus on solid tumors.
MaxCyte Signs Strategic Platform License with Curamys to Enable Cell & Gene Therapies for the Treatment of Rare Intractable Diseases
MaxCyte, Inc. and Curamys, a South Korean biotechnology company that develops cell & gene therapy using cell fusion technology to treat rare intractable diseases, including Duchenne muscular dystrophy and amyotrophic lateral sclerosis, announced the signing of a strategic platform license.
MaxCyte, Inc. announced financial results for the third quarter ended September 30, 2022.
MaxCyte, Inc. announced Company management will participate in the following investor conferences:
MaxCyte, Inc. today announced that it will release financial results for the third quarter of 2022 after the U.S. market close on Wednesday, November 9th , 2022.
MaxCyte Signs Strategic Platform License with Vertex Pharmaceuticals to Advance CRISPR/Cas9-based Gene-editing Program
MaxCyte, Inc. today announces the signing of a strategic platform license (SPL) with Vertex Pharmaceuticals Incorporated, a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases.
MaxCyte, Inc. announced that it has relocated its headquarters to 9713 Key West Avenue in Rockville, Maryland, 20850, within Maryland’s I-270 Biotech Corridor.
MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT) today announced Company management will present at the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13th at 4:40 p.m. Eastern Time.
MaxCyte, Inc. announced financial results for the second quarter and six months ended June 30, 2022.
MaxCyte, Inc. today announced that it will release financial results for the second quarter of 2022 after the U.S. market close on Wednesday, August 10th , 2022.
MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), today announces the signing of a strategic platform license (SPL) with LG Chem Ltd., a globally diversified chemical company established in petrochemical, advanced materials and bio-technology, aiming to create new value for its customers based on science.
MaxCyte, Inc. announced that, on May 10, 2022, the Compensation Committee of MaxCyte’s Board of Directors granted stock options to purchase an aggregate of 73,700 shares of MaxCyte’s common stock to six newly hired employees.